



FUSION IP PLC

("Fusion IP" or "the Company")

"MedaPhor announces Rigshospitalet, Copenhagen as first European customer for ScanTrainer"

Fusion IP plc (AIM: FIP), the university IP commercialisation company that turns world class research into business, is pleased to announce that MedaPhor, the Cardiff based ultrasound simulation company, has announced that Rigshospitalet in Copenhagen is the first European hospital to install its revolutionary Scantrainer ultrasound simulation system.

ScanTrainer is a virtual 'real feel' ultrasound-training simulator that provides students with a 24/7, educationally driven, training programme that replicates the real scan experience. Trainees can literally 'feel' what they see on the computer screen in order to develop the complex mix of cognitive skills and eye-hand movement coordination; but without the need for an ultrasound machine, a patient and considerably reduced direct supervision by an expert.

Rigshospitalet is one of Scandinavia's leading hospitals and the system has been installed in their Obstetrics and Gynaecology department as an advanced simulation-based training aid for the teaching of obstetrics and gynaecology skills to sonographers, OBGYN trainees and specialists.

Prof Ann Tabor of Rigshospitalet said:

"The number of young doctors who need training in obstetrical and gynecologic scanning is increasing and it is quite an intimate situation for a learning process. We are certain that the ScanTrainer will be a great tool for acquiring some of the necessary skills before examining the patients."

Prof Nazar Amso, Founder and Non-executive Chairman of MedaPhor, added:

"It's gratifying to see that MedaPhor has been able to transform, in a relatively short time, virtual ultrasound simulation for training from a concept into state-of-the-art ScanTrainer, that is recognised world-wide. We're grateful for the support we have received from Cardiff University and our Principal investors Fusion IP and Finance Wales."

David Baynes, CEO of Fusion IP, commented:

"This is more excellent news for MedaPhor. Following on so quickly from their first US sale, the installation in Copenhagen demonstrates the potential for MedaPhor to grow sales of its revolutionary ultrasound training simulator in both the US and Europe."

For further information please contact:

Fusion IP

David Baynes, CEO

+44 (0) 114 275 5555

MedaPhor

Stuart Gall CEO

+44 (0) 7795008967

Seymour Pierce

Freddy Crossley , Corporate Finance
Catherine Leftley, Corporate Finance
David Banks, Corporate Broking

+44 (0) 20 7107 8000

About Fusion IP

Fusion IP plc (Fusion) was established in 2002 to commercialise university-generated intellectual property. It has long-term exclusive agreements with two of the UK's leading research intensive universities, the University of Sheffield and Cardiff University, giving it exclusive access to a combined R&D spend of over £185m a year.

Fusion's first agreement was a ten-year exclusive arrangement with the University of Sheffield, giving it the right to commercialise (through the creation of spin-out companies and licensing) research, owned by the University, initially in the area of medical life sciences. This agreement was expanded in July 2008 to include all non-life science research-generated IP such as energy, engineering and electronics. Fusion has significant shareholdings in a portfolio of University of Sheffield spin-out companies including Simcyp, Magnomatics, Diurnal and Phase Focus.

In January 2007, Fusion completed a ten year exclusive agreement with Cardiff University, also giving it the right to commercialise (through the creation of spin-out companies) Cardiff University's research-generated IP. Fusion has significant shareholdings in a portfolio of Cardiff University spin-out companies including Mesuro, Asalus and MedaPhor.

On 2 December 2009 Fusion announced that it had raised approximately £3.2 million through a fund raising and that as a result, IP Group held approximately 19.8% of Fusion. Fusion has also entered into a Co-Investment Agreement with IP Group, in which IP Group has the right to acquire for cash, 20% of Fusion's equity in any new portfolio company. As Fusion normally owns 60% of any new portfolio company at start-up, IP Group's shareholding would normally equate to a 12% stake in the new portfolio company.

Fusion IP also has a Memorandum of Understanding with Finance Wales, the provider of commercial funding to Wales-based SMEs, which outlines a strategy of co-investment in opportunities arising from the Cardiff Agreement.

For more information visit www.fusionip.co.uk